Selected article for: "admission intensive care and liver function"
Author: Lopez-Mendez, Ivan; Aquino-Matus, Jorge; Gall, Sofia Murua-Beltrán; Prieto-Nava, Jose D.; Juarez-Hernandez, Eva; Uribe, Misael; Castro-Narro, Graciela
Title: Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19)
  • Cord-id: 61gtx2h2
  • Document date: 2020_10_21
    • ID: 61gtx2h2
    Snippet: INTRODUCTION AND OBJECTIVES: Liver function tests (LFT) abnormalities are reported in up to 50% of COVID-19 patients, metabolic comorbidities are associated with poorer outcomes. The aim of the study is to determine prevalence of liver steatosis and fibrosis in patients with COVID-19 and their association with clinical outcomes. MATERIAL AND METHODS: Retrospective study in hospitalized COVID-19 patients. Risk for liver steatosis was estimated by HSI > 36, and risk for advanced liver fibrosis wit
    Document: INTRODUCTION AND OBJECTIVES: Liver function tests (LFT) abnormalities are reported in up to 50% of COVID-19 patients, metabolic comorbidities are associated with poorer outcomes. The aim of the study is to determine prevalence of liver steatosis and fibrosis in patients with COVID-19 and their association with clinical outcomes. MATERIAL AND METHODS: Retrospective study in hospitalized COVID-19 patients. Risk for liver steatosis was estimated by HSI > 36, and risk for advanced liver fibrosis with APRI > 1.0, NAFLD FS > 0.675 and/or FIB-4 > 3.25. Clinical outcomes were admission to Intensive Care Unit (ICU) and mortality. RESULTS: Of 155 patients, 71.6% were male (n = 111), and 28.4% (n = 44) were obese. Abnormal LFT were present in 96.8% (n = 150), prevalence of steatosis was 42.6% (n = 66) and of significative liver fibrosis was 44.5% (n = 69). Liver fibrosis by FIB-4 was associated with risk of ICU admission (OR 1.74 [95%CI 1.74-2.68; p = 0.023]) and mortality (OR 6.45 [95%CI 2.01-20.83, p = 0.002]), no independent associations were found. CONCLUSIONS: The prevalence of steatosis and significant liver fibrosis was high in COVID-19 patients but was not associated with clinical outcomes.

    Search related documents:
    Co phrase search for related documents
    • abnormal ast and acute respiratory syndrome coronavirus: 1, 2, 3
    • abnormal ast and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • abnormal ast and liver disease relationship: 1
    • abnormal lft and acute respiratory syndrome: 1
    • abnormal lft and acute respiratory syndrome coronavirus: 1
    • abnormal lft and liver disease: 1, 2
    • abnormality present and acute respiratory syndrome: 1
    • abnormality present and acute respiratory syndrome coronavirus: 1
    • acute respiratory syndrome and liver assessment: 1, 2, 3, 4
    • acute respiratory syndrome and liver assessment model: 1
    • acute respiratory syndrome and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and liver disease relationship: 1
    • acute respiratory syndrome and liver expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute respiratory syndrome and liver fibrosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory syndrome coronavirus and liver assessment: 1, 2, 3
    • acute respiratory syndrome coronavirus and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome coronavirus and liver disease relationship: 1
    • acute respiratory syndrome coronavirus and liver expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory syndrome coronavirus and liver fibrosis: 1, 2, 3, 4, 5, 6, 7